By its marketing partner Mylan
Natco Pharma announced that its marketing partner Mylan N.V., has launched in the US the first Glatiramer Acetate Injection 40 mg/mL for 3 times-a-week injection that is an AP rated substitutable generic version of Teva's Copaxone 40mg/mL, as well as Glatiramer Acetate Injection 20 mg/mL for once-daily injection, an AP rated, substitutable generic version of Teva's Copaxone 20mg/mL.These products are indicated for the treatment of patients with relapsing forms of multiple sclerosis, a chronic inflammatory disease of the central nervous system. Shipments to customers have commenced.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content